What is Leerink Partnrs' Forecast for ANIP Q1 Earnings?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of ANI Pharmaceuticals in a note issued to investors on Wednesday, April 9th. Leerink Partnrs analyst F. Khurshid forecasts that the specialty pharmaceutical company will post earnings of $0.91 per share for the quarter. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for ANI Pharmaceuticals' Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.23 EPS, Q4 2025 earnings at $1.50 EPS, FY2025 earnings at $4.90 EPS and FY2026 earnings at $5.43 EPS.

Other equities research analysts have also issued reports about the stock. Guggenheim reaffirmed a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $79.75.

Remove Ads

ANI Pharmaceuticals Price Performance

ANIP traded up $0.83 during trading on Friday, hitting $69.55. 191,896 shares of the stock traded hands, compared to its average volume of 268,605. The business has a 50 day moving average price of $62.52 and a 200 day moving average price of $59.15. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.00. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -126.45 and a beta of 0.49.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ANIP. Exchange Traded Concepts LLC boosted its holdings in shares of ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $684,000 after purchasing an additional 310 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after buying an additional 364 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after buying an additional 412 shares during the period. Natixis Advisors LLC raised its holdings in shares of ANI Pharmaceuticals by 2.3% during the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock valued at $1,028,000 after acquiring an additional 417 shares in the last quarter. Finally, US Bancorp DE raised its stake in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the transaction, the vice president now owns 80,145 shares of the company's stock, valued at $5,526,799.20. The trade was a 0.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock valued at $197,792 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.